Imatinib-mesylate for all patients with hypereosinophilic syndrome?

Some recent papers have focused on the activity of imatinib-mesylate, a selective inhibitor of tyrosine kinase, in idiopathic hypereosinophilic syndrome (HES) [1–4]. In this setting, a possible therapeutic target was identified by Cools et al. [2], who described the fusion tyrosine-kinase gene FIP1L1/PDGFRA as the result of an interstitial deletion within chromosome 4 in nine out of sixteen (56%) patients affected by HES. Of interest, although in this study the response to imatinib was strictly correlated with the presence of FIP1L1/PDGFRA rearrangement (all patients with such a molecular lesion treated with imatinib responded), only five out of nine responding patients evidenced the abnormal transcript [2]. Among the possible alternative mechanisms for the activation of the PDGFRA tyrosine-kinase domain, these authors suggested there may be a different fusion gene.

We have recently observed a t (2;4) (p24;q12) reciprocal translocation in 64-year-old male affected by HES with complete clinical, hematological and cytogenetic response.
Letter to the Editor / Leukemia Research 28 (2004) 773–774

Imatinib (100 mg per day), currently maintained after ten months of therapy with a dose of 100 mg given every other day. A preliminary molecular screening performed according to the previously described procedures [2] failed to detect FIP1L1/PDGFRA in this patient. Cytogenetic and FISH analyses (Fig. 1A) suggested the possibility of a molecular lesion different from FIP1L1/PDGFRA rearrangement. Indeed, the fusion of PDGFRA with the oncogene N-myc could be hypothesized (Fig. 1B).

A possible heterogeneity in the molecular pathogenetic mechanisms inducing HES could justify the wide spectrum of response observed in four consecutive patients we recently treated with imatinib, which ranged from an impressive and durable response to low doses in the patient with t(2;4), to the need of administering higher doses of the drug (400 mg per day) to achieve response, until to the evidence of progressively acquired or primary resistance to doses up to 800 mg per day [5].

Since not all HES patients respond to imatinib, a relevant aspect to consider is the fact that clonal populations of CD3−/CD4+ Th2 lymphocytes may secrete large amounts of interleukin-5 (IL-5) and other cytokines, possibly involved in the pathogenesis of at least some cases of HES [6,7]. Although serum levels of IL-5 do not seem to represent a surrogate marker of response to imatinib in this disease [3], it is intriguing to note that all cases of HES responding to imatinib so far reported did not evidence the presence of T cell clones expansion, when tested [1,3]. By contrast, one patient described by Pardanani et al. [3] and the only our patient in whom an occult T cell clone could be detected, did not respond to imatinib at all. It is conceivable that "T cell-correlated" HES may have a different pathogenesis, not including constitutive activation of tyrosine-kinases. Therefore, it may be expected these forms are not responsive to imatinib.

Imatinib-mesylate is certainly a promising treatment for HES. However, the clinical and biological profile of patients who are potential responders needs to be better defined.

References


Pellegrino Musto∗
Gianni Perla
Maria Marta Minervini
Angelo Michele Carella
Unit of Hematology and Stem Cell Transplantation
IRCCS “Casa Sollievo della Sofferenza”
71013 S. Giovanni Rotondo, Italy
∗Corresponding author. Tel.: +39-0882-411389; fax: +39-0882-411389.
E-mail address: p.musto@tin.it (P. Musto).

Francesco Lo Coco
Gianfranco Catalano
Chair of Hematology, “Tor Vergata”
University, Rome, Italy
18 November 2003